戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lling for comorbidity and acuity of illness, radiocontrast administration associated with an odds rat
2  to estimate the risk of AKI associated with radiocontrast administration within each stratum.
3                               We infused the radiocontrast agent into the pancreatic ducts of wild-ty
4  exposed mouse and human acinar cells to the radiocontrast agent iohexol (Omnipaque; GE Healthcare, P
5 (10.0 mg/kg), vehicle or antagonist, and the radiocontrast agent lopamidol (2,9 g iodine/kg).
6 bitor FK506 before and after infusion of the radiocontrast agent.
7                                              Radiocontrast agents are required for radiographic proce
8                                              Radiocontrast agents cause pancreatic inflammation in mi
9 ed whether exposure of pancreatic tissues to radiocontrast agents during endoscopic retrograde cholan
10 t," "contrast medium," "contrast media," or "radiocontrast" and any of the words or phrases "nephroto
11 cr after the administration of intravascular radiocontrast are associated with adverse patient outcom
12 we created multiple estimates of the risk of radiocontrast-associated nephropathy among adult patient
13                   In conclusion, the risk of radiocontrast-associated nephropathy may be overstated i
14                Estimates of the incidence of radiocontrast-associated nephropathy vary widely and suf
15 actice because of an aversion to the risk of radiocontrast-associated nephrotoxicity ("renalism") is
16                        The perceived risk of radiocontrast-associated nephrotoxicity may influence th
17            In general, patients who received radiocontrast did not develop AKI at a clinically signif
18 e, prostaglandin inhibitors, cyclosporine A, radiocontrast dyes and volatile anesthetic agents.
19 rdiopulmonary bypass, minimizing injury from radiocontrast dyes or other nephrotoxic agents, and opti
20 empting to balance the potential benefits of radiocontrast-enhanced imaging and the risk of AKI.
21             The drug has actions relevant to radiocontrast-induced nephropathy (RCIN) that include va
22 A role for endothelin in the pathogenesis of radiocontrast-induced nephropathy has been suggested by
23  oral N-acetylcysteine for the prevention of radiocontrast-induced nephropathy have yielded inconsist
24 othelin-A receptor antagonist BMS-182,874 in radiocontrast-induced nephropathy in rats.
25 ced the marked diuresis and mTAL necrosis in radiocontrast-induced nephropathy in rats.
26                                              Radiocontrast-induced nephropathy was produced in anesth
27 unction and structure in this acute model of radiocontrast-induced nephropathy.
28 mmediate hypersensitivity reactions (IHR) to radiocontrast media (RCM).
29 ced kidney function before administration of radiocontrast media (RCM).
30 ion from acute renal failure associated with radiocontrast media treatment.
31 ich carry a negative charge similar to ionic radiocontrast media, the major cause of iatrogenic anaph
32 perative drugs, heparins, platinum salts and radiocontrast media.
33  with renal insufficiency who are to receive radiocontrast media.
34 For patients, even in uncomplicated cases of radiocontrast medium infusion during cardiac catheteriza
35 onic sodium bicarbonate infusions to prevent radiocontrast medium-induced renal failure.
36 fy its use for a group of patients receiving radiocontrast medium.
37 ence of a universally accepted definition of radiocontrast nephropathy (RCN) has hampered efforts to
38 rch on N-acetylcysteine and the incidence of radiocontrast nephropathy is too inconsistent at present
39 s likely relates to increased medication and radiocontrast use, enhanced diagnosis, and coding change
40  the complex survey design, patients to whom radiocontrast was and was not administered developed AKI

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。